Mäurer W, Yoshida Y, Kübler W
Z Kardiol. 1976 Dec;65(12):1124-38.
In 20 normal persons and in 57 patients with heart diseases with functional class I-IV (according to the classification of the New York Heart Association) the 24 hour urinary excretion of the catecholamines adrenaline, noradrenaline and dopamine and of the O2-methylated degradation products metanephrine and normetanephrine was determined. The 3 catecholamines and the 2 O-methylated derivatives were measured simultaneously using chromatographic extraction and purification (Bio-Rex 70) and selective flurometric determination. The following results could be obtained: 1. The urinary excretion of noradrenaline increased with increasing severity of the heart disease. 2. In patients with severe congestive heart failure (functional class IV) in addition the adrenaline excretion in addition the adrenaline excretion increased significantly. 3. There was no relationship between the urinary excretion of dopamine and the severity of the heart disease. 4. The ratio of noradrenaline excretion to dopamine excretion increased with increasing severity of the heart disease, indicating an increased activity of dopamine-mu-hydroxylation in patients with congestive heart failure. 5. The excretion of the O-methylated degradation products metanephrine and normetanephrine in normal persons and in patients with heart diseases paralleled the excretion of the corresponding catecholamines adrenaline and noradrenaline. This indicates, that increased excretion of noradrenaline and adrenaline (Class IV) in patients with heart failure was not due to impaired catecholamine-degradation but indead to increased catecholamine-release indicating increased sympatho-adrenergic activity. These results show in addition that also in patients with heart failure O-methylation represents still the main degradation step for the inactivation of the circulating catecholamines. 6. The relationship of toal excretion of 0-methylated derivates to total excretion of adrenaline and noradrenaline, however, decreased with increasing severity of heart disease, indicating a relative impairment of O-methylation under the condition of severe congestive heart failure.
对20名正常人以及57例心功能I - IV级(根据纽约心脏协会分类)的心脏病患者,测定了儿茶酚胺肾上腺素、去甲肾上腺素和多巴胺以及O - 甲基化降解产物间甲肾上腺素和去甲变肾上腺素的24小时尿排泄量。采用色谱提取和纯化(Bio - Rex 70)及选择性荧光测定法同时测定了这3种儿茶酚胺和2种O - 甲基化衍生物。可得到以下结果:1. 去甲肾上腺素的尿排泄量随心脏病严重程度的增加而增加。2. 在重度充血性心力衰竭(心功能IV级)患者中,肾上腺素排泄量也显著增加。3. 多巴胺的尿排泄量与心脏病严重程度之间无相关性。4. 随着心脏病严重程度的增加,去甲肾上腺素排泄量与多巴胺排泄量的比值升高,表明充血性心力衰竭患者中多巴胺 - μ - 羟化酶活性增加。5. 正常人及心脏病患者中O - 甲基化降解产物间甲肾上腺素和去甲变肾上腺素的排泄量与相应儿茶酚胺肾上腺素和去甲肾上腺素的排泄量平行。这表明,心力衰竭患者中去甲肾上腺素和肾上腺素(IV级)排泄量增加并非由于儿茶酚胺降解受损,而是确实由于儿茶酚胺释放增加,提示交感 - 肾上腺素能活性增强。这些结果还表明,在心力衰竭患者中,O - 甲基化仍然是循环儿茶酚胺失活的主要降解步骤。6. 然而,随着心脏病严重程度的增加,O - 甲基化衍生物总排泄量与肾上腺素和去甲肾上腺素总排泄量的关系降低,表明在重度充血性心力衰竭情况下O - 甲基化相对受损。